Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial

被引：12

作者：

Friedlander, Michael

Gebski, Val

Gibbs, Emma

Bloomfield, Ralph

Hilpert, Felix

Wenzel, Lari B.

Joly, Florence

Eek, Daniel

Rodrigues, Manuel

Clamp, Andrew R.

Penson, Richard T.

Provencher, Diane M.

Korach, Jacob

Huzarski, Tomasz

Vidal, Laura

Salutari, Vanda

Scott, Clare L.

Nicoletto, Maria Ornella

Tamura, Kenji

Pujade-Lauraine, Eric

机构：

[1] Prince Wales Hosp, UNSW Clin Sch, Randwick, NSW, Australia

[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[3] AstraZeneca, Cambridge, England

[4] AGO, Hamburg, Germany

[5] Krankenhaus Jerusalem Hamburg, Hamburg, Germany

[6] Univ Calif Irvine, Irvine, CA USA

[7] GINECO, Caen, France

[8] Reg Ctr Control Canc Francois Baclesse, Caen, France

[9] AstraZeneca, Gothenburg, Sweden

[10] Inst Curie, Paris, France

[11] Christie NHS Fdn Trust, Manchester, Lancs, England

[12] Univ Manchester, Manchester, Lancs, England

[13] Harvard Med Sch, Boston, MA 02115 USA

[14] Univ Montreal, Montreal, PQ, Canada

[15] Tel Aviv Univ, Sheba Med Ctr, Tel Hashomer, Israel

[16] Pomeranian Med Univ, Szczecin, Poland

[17] Hosp Clin Barcelona, Barcelona, Spain

[18] Policlin Univ Gemelli, Rome, Italy

[19] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia

[20] Inst Oncol Veneto, Padua, Italy

[21] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, Tokyo, Japan

[22] Univ Paris 05, AP HP, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.5507

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5507

引用

页数：6